Mapi Pharma

Company Overview

Snapshot

Founded in January 2008 by Ehud Marom, Mapi Pharma operates with 51–200 employees. The company has secured $42.5 million in total capital across four funding rounds from three investors. A significant milestone for the company was the announcement of positive top-line results from its GA Depot Phase III trial for Relapsing forms of Multiple Sclerosis (RMS) in September 2022.

Business overview

Mapi Pharma is a clinical-stage pharmaceutical company focused on developing proprietary pharmaceuticals, including lifecycle management products. Its core offerings include Depot long-acting injections, complex active pharmaceutical ingredients, and advanced formulations. The company's lead product, Glatiramer Acetate Depot, is a once-monthly injection for multiple sclerosis. Mapi Pharma also develops treatments for neuropathic pain, epilepsy, and schizophrenia, operating within the Health Tech & Life Sciences sector, specifically targeting the Pharmaceuticals market.

Strategic signal

In September 2022, Mapi Pharma announced positive top-line results from its GA Depot Phase III trial for Relapsing forms of Multiple Sclerosis (RMS). This development is significant as it validates the potential efficacy and safety of their lead product, positioning it as a promising long-acting treatment option in the competitive multiple sclerosis market. For investors, this signals strong progress in their clinical pipeline and potential for future market entry and commercialization.

Company Intelligence Q&A

What was a key clinical development for Mapi Pharma in 2022?

In September 2022, Mapi Pharma announced positive top-line results from its.

Did Mapi Pharma secure any intellectual property in 2022?

In March 2022, Mapi Pharma received a U.S. patent covering methods of suppressing or alleviating primary or secondary progressive multiple sclerosis with a sustained-release Glatiramer Acetate Depot.

What strategic partnership did Mapi Pharma establish in 2021?

In October 2021, Mapi Pharma signed an agreement with Gaelan Medical Trade LLC to exclusively market and distribute Mapi products in the UAE, expanding its commercial reach in the Middle East.

What was Mapi Pharma's activity regarding its GA Depot product in 2019?

In October 2019, Mapi Pharma announced the first patient enrollment in the Phase III clinical trial of GA Depot for Relapsing Multiple Sclerosis (RMS), advancing its key product toward market.